CIBC World Markets Boosts Stake in Elevance Health by 24.4%

CIBC World Markets Inc. has increased its investment in Elevance Health, Inc., raising its stake by 24.4% during the third quarter of the year. According to HoldingsChannel.com, the financial institution now holds 19,807 shares of Elevance Health, valued at approximately $6.4 million following the acquisition of an additional 3,879 shares.

This move reflects a broader trend among institutional investors, many of whom are adjusting their positions in Elevance Health. For instance, Vermillion & White Wealth Management Group LLC significantly enhanced its stake by 94.9% in the second quarter, acquiring 76 shares to reach a total worth of $30,000. Other notable transactions include BOK Financial Private Wealth Inc., which established a new position valued at $32,000, and Physician Wealth Advisors Inc., which increased its holdings by an impressive 331.6% during the same period.

Elevance Health’s Stock Performance and Dividend Announcement

As of the latest market data, Elevance Health shares opened at $346.49. The company boasts a market capitalization of $76.47 billion, with a price-to-earnings (P/E) ratio of 13.79. The stock has fluctuated significantly over the past year, reaching a low of $273.71 and a high of $458.75. The firm also announced a quarterly dividend of $1.72, to be paid on March 25, 2024, to shareholders on record by March 10. This dividend marks an increase from the previous quarter’s payout of $1.71, representing an annualized yield of 2.0%.

Elevance Health’s dividend payout ratio currently stands at 27.23%, indicating a sustainable dividend policy amid its financial growth.

Analysts Adjust Price Targets for Elevance Health

In recent days, several analysts have revised their price targets for Elevance Health. UBS Group has set a target of $400.00, while Sanford C. Bernstein adjusted theirs from $431.00 to $409.00 with an “outperform” rating. Guggenheim also reduced its target from $414.00 to $396.00, maintaining a “buy” rating. Wolfe Research set a target of $425.00, and Zacks Research upgraded the stock from a “strong sell” to a “hold” rating.

In total, twelve analysts currently rate Elevance Health as a Buy, while nine suggest holding the stock, with only one recommending a sell. The consensus rating reflects a moderate buy with an average target price of $390.55, according to data from MarketBeat.

Elevance Health, headquartered in Indianapolis, is a major player in the health benefits sector, providing a wide array of health insurance products. The company, which rebranded from Anthem, Inc. in 2022, continues to focus on integrated healthcare solutions under various established brands. Under the leadership of Chief Executive Officer Gail Boudreaux, Elevance Health remains committed to enhancing its service offerings across individual, employer, and government healthcare programs.

For further updates on Elevance Health and its market movements, interested parties may refer to HoldingsChannel.com for the latest 13F filings and insider trades.